Skip to main content
SpringerLink
Log in

ACE Cardiovascular Protection: EUROPA versus HOPE

  • Editorial Introduction
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barton M, Haudenschild CC. Endothelium and atherogenesis: Endothelial therapy revisited. J Cardiovasc Pharmacol 2001;38(Suppl 2):S23–S25.

    Google Scholar 

  2. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056–2069.

    Google Scholar 

  3. Flather MD, Yusuf S, KØber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Lancet 2000;355:1575–1581.

    Google Scholar 

  4. Wing L, Reid C, Ryan P, et al. for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592.

    Google Scholar 

  5. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. AIPRD Study Group. Ann Intern Med 2003;139:244–252.

    Google Scholar 

  6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

  7. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. PROGRESS Collaborative Group. Lancet 2001;3581033–3581041.

  8. Dzau, VJ, Bernstein, K, Celermajer, D, et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001 (Suppl.):1L–20L.

    Google Scholar 

  9. Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: A consensus report. Cardiovasc Drugs Ther 2002;16:149–160.

    Google Scholar 

  10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153.

    Google Scholar 

  11. The EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782–788.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Southampton General Hospital, Tremona Rd, Shirley, Southampton, UK, SO16 6YD

    Christopher J. Boos

  2. Department of Cardiology, Portsmouth Hospitals Trust, Milton R, Portsmouth, UK, PO3 6AD

    Matthew Dawes

Authors
  1. Christopher J. Boos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Dawes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boos, C.J., Dawes, M. ACE Cardiovascular Protection: EUROPA versus HOPE. Cardiovasc Drugs Ther 18, 179–180 (2004). https://doi.org/10.1023/B:CARD.0000033657.01493.6e

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:CARD.0000033657.01493.6e

Search

Navigation